Header Logo

Navid Sobhani

TitlePostdoc Fellows and Associates
InstitutionBaylor College of Medicine
DepartmentPostDoc
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Shi X, Ding J, Zheng Y, Wang J, Sobhani N, Neeli P, Wang G, Zheng J, Chai D. HMGB1/GPC3 dual targeting vaccine induces dendritic cells-mediated CD8+T cell immune response and elicits potential therapeutic effect in hepatocellular carcinoma. iScience. 2023 Mar 17; 26(3):106143. PMID: 36879804; PMCID: PMC9984564.
      Citations:    
    2. Sobhani N, Bouch? V, Aldegheri G, Rocca A, D'Angelo A, Giudici F, Bottin C, Donofrio CA, Pinamonti M, Ferrari B, Panni S, Cominetti M, Aliaga J, Ungari M, Fioravanti A, Zanconati F, Generali D. Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report. Biomedicines. 2023 Jan 22; 11(2). PMID: 36830847; PMCID: PMC9953166.
      Citations:    
    3. D'Angelo A, Kilili H, Chapman R, Generali D, Tinhofer I, Luminari S, Donati B, Ciarrocchi A, Giannini R, Moretto R, Cremolini C, Pietrantonio F, Sobhani N, Bonazza D, Prins R, Song SG, Jeon YK, Pisignano G, Cinelli M, Bagby S, Urrutia AO. Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analyses. PLoS One. 2023; 18(1):e0280364. PMID: 36649303; PMCID: PMC9844904.
      Citations:    Fields:    Translation:HumansCells
    4. Wang Q, Chai D, Sobhani N, Sun N, Neeli P, Zheng J, Tian H. C1QBP regulates mitochondrial plasticity to impact tumor progression and antitumor immune response. Front Physiol. 2022; 13:1012112. PMID: 36467687; PMCID: PMC9713694.
      Citations:    
    5. Abbasian MH, Ardekani AM, Sobhani N, Roudi R. The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment. Cancers (Basel). 2022 Oct 20; 14(20). PMID: 36291929; PMCID: PMC9600051.
      Citations:    
    6. D'Angelo A, Giudici F, Chapman R, Darlow J, Kilili H, Sobhani N, Cinelli M, Cappelletti MR, Strina C, Milani M, Generali D. Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study. Curr Issues Mol Biol. 2022 Sep 15; 44(9):4255-4267. PMID: 36135204; PMCID: PMC9497904.
      Citations:    
    7. D'Angelo A, Chapman R, Sirico M, Sobhani N, Catalano M, Mini E, Roviello G. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next. Cancer Chemother Pharmacol. 2022 09; 90(3):191-205. PMID: 35953604; PMCID: PMC9402760.
      Citations:    
    8. Sobhani N, Scaggiante B, Morris R, Chai D, Catalano M, Tardiel-Cyril DR, Neeli P, Roviello G, Mondani G, Li Y, Sobhani N, Scaggiante B, Morris R, Chai D, Catalano M, Tardiel-Cyril DR, Neeli P, Roviello G, Mondani G, Li Y. Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials. Cancer Treat Rev. 2022 Sep; 109:102429. PMID: 35759856; PMCID: PMC9217071.
      Citations:    Fields:    
    9. Sobhani N, Chahwan R, Roudi R, Morris R, Volinia S, Chai D, D'Angelo A, Generali D, Sobhani N, Chahwan R, Roudi R, Morris R, Volinia S, Chai D, D'Angelo A, Generali D, Volinia S. Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer. Cancers (Basel). 2022 Jun 15; 14(12). PMID: 35740618; PMCID: PMC9221286.
      Citations:    
    10. Chai D, Shi SY, Sobhani N, Ding J, Zhang Z, Jiang N, Wang G, Li M, Li H, Zheng J, Bai J, Chai D, Shi SY, Sobhani N, Ding J, Zhang Z, Jiang N, Wang G, Li M, Li H, Zheng J, Bai J. IFI35 Promotes Renal Cancer Progression by Inhibiting pSTAT1/pSTAT6-Dependent Autophagy. Cancers (Basel). 2022 Jun 09; 14(12). PMID: 35740527; PMCID: PMC9221357.
      Citations:    
    11. Roudi R, D'Angelo A, Sirico M, Sobhani N, Roudi R, D'Angelo A, Sirico M, Sobhani N. Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. Int Immunopharmacol. 2021 Dec; 101(Pt A):108322. PMID: 34735916.
      Citations: 6     Fields:    Translation:HumansAnimals
    12. Sobhani N, Roviello G, D'Angelo A, Roudi R, Neeli PK, Generali D, Sobhani N, Roviello G, D'Angelo A, Roudi R, Neeli PK, Generali D. p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis. Molecules. 2021 Oct 14; 26(20). PMID: 34684792; PMCID: PMC8541220.
      Citations: 3     Fields:    Translation:Humans
    13. Roviello G, D'Angelo A, Sirico M, Pittacolo M, Conter FU, Sobhani N, Roviello G, D'Angelo A, Sirico M, Pittacolo M, Conter FU, Sobhani N. Author Correction to: Advances in anti-BRAF therapies for lung cancer. Invest New Drugs. 2021 Oct; 39(5):1456. PMID: 33646490; PMCID: PMC8587236.
      Citations:    Fields:    
    14. Sobhani N, Neeli PK, D'Angelo A, Pittacolo M, Sirico M, Galli IC, Roviello G, Nesi G, Sobhani N, Neeli PK, D'Angelo A, Pittacolo M, Sirico M, Galli IC, Roviello G, Nesi G. AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption. Int J Mol Sci. 2021 May 24; 22(11). PMID: 34073713; PMCID: PMC8197232.
      Citations: 2     Fields:    Translation:HumansCells
    15. Fan C, Qu H, Wang X, Sobhani N, Wang L, Liu S, Xiong W, Zeng Z, Li Y, Fan C, Qu H, Wang X, Sobhani N, Wang L, Liu S, Xiong W, Zeng Z, Li Y. Cancer/testis antigens: from serology to mRNA cancer vaccine. Semin Cancer Biol. 2021 11; 76:218-231. PMID: 33910064.
      Citations: 3     Fields:    Translation:HumansAnimals
    16. Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y, Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y. CTLA-4 in Regulatory T Cells for Cancer Immunotherapy. Cancers (Basel). 2021 Mar 22; 13(6). PMID: 33809974; PMCID: PMC8005092.
      Citations: 23     
    17. Sobhani N, Fassl A, Mondani G, Generali D, Otto T, Sobhani N, Fassl A, Mondani G, Generali D, Otto T. Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer. Cells. 2021 02 01; 10(2). PMID: 33535617; PMCID: PMC7912842.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    18. Roviello G, D'Angelo A, Sirico M, Pittacolo M, Conter FU, Sobhani N, Roviello G, D'Angelo A, Sirico M, Pittacolo M, Conter FU, Sobhani N. Advances in anti-BRAF therapies for lung cancer. Invest New Drugs. 2021 06; 39(3):879-890. PMID: 33474634; PMCID: PMC8068629.
      Citations: 5     Fields:    Translation:Humans
    19. Sirico M, Bernocchi O, Sobhani N, Giudici F, Corona SP, Vernieri C, Nichetti F, Cappelletti MR, Milani M, Strina C, Cervoni V, Barbieri G, Ziglioli N, Dester M, Bianchi GV, De Braud F, Generali D, Sirico M, Bernocchi O, Sobhani N, Giudici F, Corona SP, Vernieri C, Nichetti F, Cappelletti MR, Milani M, Strina C, Cervoni V, Barbieri G, Ziglioli N, Dester M, Bianchi GV, De Braud F, Generali D. Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Cancers (Basel). 2020 Nov 10; 12(11). PMID: 33182575; PMCID: PMC7697290.
      Citations: 2     
    20. D'Angelo A, Sobhani N, Chapman R, Bagby S, Bortoletti C, Traversini M, Ferrari K, Voltolini L, Darlow J, Roviello G, D'Angelo A, Sobhani N, Chapman R, Bagby S, Bortoletti C, Traversini M, Ferrari K, Voltolini L, Darlow J, Roviello G, Traversini M. Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. Cancers (Basel). 2020 Nov 06; 12(11). PMID: 33172113; PMCID: PMC7694780.
      Citations: 11     
    21. Schettini F, Sobhani N, Ianza A, Triulzi T, Molteni A, Lazzari MC, Strina C, Milani M, Corona SP, Sirico M, Bernocchi O, Giudici F, Cappelletti MR, Ciruelos E, Jerusalem G, Loi S, Fox SB, Generali D, Schettini F, Sobhani N, Ianza A, Triulzi T, Molteni A, Lazzari MC, Strina C, Milani M, Corona SP, Sirico M, Bernocchi O, Giudici F, Cappelletti MR, Ciruelos E, Jerusalem G, Loi S, Fox SB, Generali D, Jerusalem G. Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. Breast Cancer Res Treat. 2020 Nov; 184(2):421-431. PMID: 32770287; PMCID: PMC7599144.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    22. Flores-Villanueva P, Sobhani N, Wang X, Li Y, Flores-Villanueva P, Sobhani N, Wang X, Li Y. MR1-Restricted T Cells in Cancer Immunotherapy. Cancers (Basel). 2020 Aug 03; 12(8). PMID: 32756356; PMCID: PMC7464881.
      Citations: 1     
    23. Sobhani N, Sirico M, Generali D, Zanconati F, Scaggiante B, Sobhani N, Sirico M, Generali D, Zanconati F, Scaggiante B. Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer. World J Clin Oncol. 2020 Jul 24; 11(7):450-463. PMID: 32821651; PMCID: PMC7407926.
      Citations: 1     
    24. Sobhani N, D'Angelo A, Wang X, Young KH, Generali D, Li Y, Sobhani N, D'Angelo A, Wang X, Young KH, Generali D, Li Y. Mutant p53 as an Antigen in Cancer Immunotherapy. Int J Mol Sci. 2020 Jun 08; 21(11). PMID: 32521648; PMCID: PMC7312027.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    25. D'Angelo A, Sobhani N, Bagby S, Casadei-Gardini A, Roviello G, D'Angelo A, Sobhani N, Bagby S, Casadei-Gardini A, Roviello G. Cabozantinib as a second-line treatment option in hepatocellular carcinoma. Expert Rev Clin Pharmacol. 2020 Jun; 13(6):623-629. PMID: 32394749.
      Citations: 5     Fields:    Translation:HumansAnimals
    26. Sobhani N, Corona SP, Roviello G, Bagby S, D'Angelo A, Iezzi G, Generali D, Sobhani N, Corona SP, Roviello G, Bagby S, D'Angelo A, Iezzi G, Generali D. Immune-gene signature: a new tool for patient selection for checkpoint inhibitors? Future Oncol. 2020 Jul; 16(19):1327-1330. PMID: 32396404.
      Citations: 1     Fields:    Translation:HumansCells
    27. Roviello G, Sobhani N, Corona SP, D'Angelo A, Roviello G, Sobhani N, Corona SP, D'Angelo A. Corticosteroid switch after progression on abiraterone acetate plus prednisone. Int J Clin Oncol. 2020 Feb; 25(2):240-246. PMID: 31705219.
      Citations: 1     Fields:    Translation:Humans
    28. D'Angelo A, Sobhani N, Roviello G, Bagby S, Bonazza D, Bottin C, Giudici F, Zanconati F, De Manzini N, Guglielmi A, Generali D, D'Angelo A, Sobhani N, Roviello G, Bagby S, Bonazza D, Bottin C, Giudici F, Zanconati F, De Manzini N, Guglielmi A, Generali D, Bonazza D, Bottin C, Giudici F, Zanconati F, De Manzini N. Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma. PLoS One. 2019; 14(8):e0219566. PMID: 31381571; PMCID: PMC6681957.
      Citations: 10     Fields:    Translation:HumansCells
    29. Roviello G, Conter FU, Mini E, Generali D, Traversini M, Lavacchi D, Nobili S, Sobhani N, Roviello G, Conter FU, Mini E, Generali D, Traversini M, Lavacchi D, Nobili S, Sobhani N. Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer. Cancer Chemother Pharmacol. 2019 10; 84(4):669-677. PMID: 31187168.
      Citations: 5     Fields:    Translation:Humans
    30. Roviello G, D'Angelo A, Generali D, Pittacolo M, Ganzinelli M, Iezzi G, Manzini N, Sobhani N, Roviello G, D'Angelo A, Generali D, Pittacolo M, Ganzinelli M, Iezzi G, Manzini N, Sobhani N, Manzini N. Avelumab in gastric cancer. Immunotherapy. 2019 06; 11(9):759-768. PMID: 31060469.
      Citations: 4     Fields:    Translation:Humans
    31. Sobhani N, D'Angelo A, Pittacolo M, Roviello G, Miccoli A, Corona SP, Bernocchi O, Generali D, Otto T, Sobhani N, D'Angelo A, Pittacolo M, Roviello G, Miccoli A, Corona SP, Bernocchi O, Generali D, Otto T. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer. Cells. 2019 04 06; 8(4). PMID: 30959874; PMCID: PMC6523967.
      Citations: 45     Fields:    Translation:HumansAnimals
    32. Sobhani N, Roviello G, Pivetta T, Ianza A, Bonazza D, Zanconati F, Giudici F, Bottin C, Corona SP, Guglielmi A, Rizzardi C, Milione M, Cortale M, Confalonieri M, Generali D, Sobhani N, Roviello G, Pivetta T, Ianza A, Bonazza D, Zanconati F, Giudici F, Bottin C, Corona SP, Guglielmi A, Rizzardi C, Milione M, Cortale M, Confalonieri M, Generali D. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma. Mol Biol Rep. 2019 Jun; 46(3):2713-2720. PMID: 30840203.
      Citations: 6     Fields:    Translation:HumansCells
    33. Roviello G, Generali D, Sobhani N, Roviello G, Generali D, Sobhani N. The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer-a commentary on the E5103 randomized phase III clinical study. Transl Cancer Res. 2019 Mar; 8(Suppl 2):S94-S96. PMID: 35117071; PMCID: PMC8797650.
      Citations: 1     
    34. Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B, Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B. Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer. World J Clin Oncol. 2018 Dec 20; 9(8):172-179. PMID: 30622925; PMCID: PMC6314865.
      Citations: 5     
    35. Sobhani N, Generali D, D'Angelo A, Aieta M, Roviello G, Sobhani N, Generali D, D'Angelo A, Aieta M, Roviello G. Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer. Invest New Drugs. 2018 12; 36(6):1133-1137. PMID: 30083960.
      Citations: 9     Fields:    Translation:HumansCells
    36. Sobhani N, Ianza A, D'Angelo A, Roviello G, Giudici F, Bortul M, Zanconati F, Bottin C, Generali D, Sobhani N, Ianza A, D'Angelo A, Roviello G, Giudici F, Bortul M, Zanconati F, Bottin C, Generali D. Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer. Cells. 2018 Jul 15; 7(7). PMID: 30011957; PMCID: PMC6071019.
      Citations: 18     Fields:    
    37. Roviello G, Corona SP, Bozza G, Aieta M, Generali D, Rodriquenz MG, Mileo AM, Imperatori M, Ianza A, Conca R, Sobhani N, Roviello G, Corona SP, Bozza G, Aieta M, Generali D, Rodriquenz MG, Mileo AM, Imperatori M, Ianza A, Conca R, Sobhani N. Lenvatinib for the treatment of renal cell carcinoma. Expert Opin Investig Drugs. 2018 05; 27(5):507-512. PMID: 29718721.
      Citations: 3     Fields:    Translation:HumansAnimals
    38. Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B, Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B. Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives? World J Clin Oncol. 2018 Apr 10; 9(2):26-32. PMID: 29651384; PMCID: PMC5893994.
      Citations: 10     
    39. Sobhani N, Roviello G, Corona SP, Scaltriti M, Ianza A, Bortul M, Zanconati F, Generali D, Sobhani N, Roviello G, Corona SP, Scaltriti M, Ianza A, Bortul M, Zanconati F, Generali D. The prognostic value of PI3K mutational status in breast cancer: A meta-analysis. J Cell Biochem. 2018 06; 119(6):4287-4292. PMID: 29345357; PMCID: PMC5995110.
      Citations: 27     Fields:    Translation:HumansCells
    40. Sobhani N, Corona SP, Bonazza D, Ianza A, Pivetta T, Roviello G, Cortale M, Guglielmi A, Zanconati F, Generali D, Sobhani N, Corona SP, Bonazza D, Ianza A, Pivetta T, Roviello G, Cortale M, Guglielmi A, Zanconati F, Generali D, Bonazza D, Pivetta T, Cortale M, Zanconati F. Advances in systemic therapy for malignant mesothelioma: future perspectives. Future Oncol. 2017 Oct; 13(23):2083-2101. PMID: 28984470.
      Citations: 1     Fields:    Translation:Humans
    41. Roviello G, Sobhani N, Generali D, Roviello G, Sobhani N, Generali D. Bevacizumab in small cell lung cancer. Ann Transl Med. 2017 Sep; 5(17):361. PMID: 28936455; PMCID: PMC5599295.
      Citations: 3     
    42. Sobhani N, Roviello G, Corona SP, Ianza A, Zanconati F, Generali D, Sobhani N, Roviello G, Corona SP, Ianza A, Zanconati F, Generali D. Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma. Lung Cancer. 2017 12; 114:103-105. PMID: 28757047.
      Citations:    Fields:    Translation:Humans
    43. Sobhani N, Generali D, Roviello G, Sobhani N, Generali D, Roviello G. PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy. EBioMedicine. 2017 08; 22:18-19. PMID: 28688823; PMCID: PMC5552208.
      Citations: 2     Fields:    Translation:Humans
    44. Corona SP, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M, Zanconati F, Generali D, Corona SP, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M, Zanconati F, Generali D. Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives. Med Oncol. 2017 07; 34(7):130. PMID: 28616710.
      Citations:    Fields:    
    45. Corona SP, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M, Zanconati F, Generali D, Corona SP, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M, Zanconati F, Generali D. Advances in systemic therapy for metastatic breast cancer: future perspectives. Med Oncol. 2017 Jul; 34(7):119. PMID: 28526922.
      Citations: 18     Fields:    Translation:Humans
    46. Sobhani N, Corona SP, Zanconati F, Generali D, Sobhani N, Corona SP, Zanconati F, Generali D. Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma. Genes Cancer. 2017 Mar; 8(3-4):495-496. PMID: 28680533; PMCID: PMC5489646.
      Citations: 7     
    Sobhani's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (108)
    Explore
    _
    Co-Authors (4)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _